Hans K Hasselbalch

Hans K Hasselbalch

Clinical Professor

Member of:

  • Internal Medicine: Haematology


  1. 2017
  2. Published

    Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development

    Andersen, M., Sajid, Z., Pedersen, R. K., Gudmand-hoeyer, J., Ellervik, C., Skov, V., Kjær, L., Pallisgaard, N., Kruse, T. A., Thomassen, M., Troelsen, J., Hasselbalch, Hans Carl & Ottesen, J. T., 2017, In: PLOS ONE. 12, 8, 18 p., e0183620.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms

    Bak, M., Sørensen, Torben Lykke, Flachs, E. M., Zwisler, A., Juel, K., Frederiksen, H. & Hasselbalch, Hans Carl, 2017, In: JAMA Ophthalmology. 135, 8, p. 835-843

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

    Bjørn, M. E. & Hasselbalch, Hans Carl, 2017, In: Expert Review of Hematology. 10, 5, p. 393-404

    Research output: Contribution to journalReviewResearchpeer-review

  5. Published

    A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents

    Brochmann, N., Flachs, E. M., Christensen, A. I., Andersen, Christen Bertel L, Juel, K., Hasselbalch, Hans Carl & Zwisler, A., 2017, In: Clinical Epidemiology. 9, p. 141-150

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera

    Enblom-Larsson, A., Girodon, F., Bak, M., Hersby, D., Jooste, V., Hasselbalch, Hans Carl, Johansson, P. & Andreasson, B., 2017, In: British Journal of Haematology. 177, 5, p. 800-805

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms

    Hansen, I. O., Sørensen, A. L. & Hasselbalch, Hans Carl, 2017, In: European Journal of Haematology. 98, 1, p. 75-84

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Anemia is present years before myelodysplastic syndrome diagnosis: Results from the pre-diagnostic period

    Hansen, Jakob Werner, Sandholdt, H., Siersma, Volkert Dirk, mxz703, mxz703, Holmberg, S., Bjerrum, O. W., Hasselbalch, Hans Carl, Olivarius, Niels de Fine, Grønbæk, Kirsten & Andersen, Christen Bertel L, Jul 2017, In: American Journal of Hematology. 92, 7, p. E130-E132 3 p.

    Research output: Contribution to journalComment/debateResearchpeer-review

  9. Published

    Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: The proof of concept in early myelofibrosis

    Hasselbalch, Hans Carl, 2017, In: Cancer. 123, 14, p. 2600-2603

    Research output: Contribution to journalEditorialResearch

  10. Published

    The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

    Holmstrom, M. O., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2017, In: OncoImmunology. 6, 11, 3 p., e1358334.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

    Holmström, M. O., Hjortso, M. D., Ahmad, S. M., Met, Özcan, Martinenaite, E., Riley, C., Straten, P., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2017, In: Leukemia. 31, p. 495-498

    Research output: Contribution to journalLetterResearchpeer-review

ID: 2849472